Company Outline
| Company Name | Novacellum Inc. |
|---|---|
| Established | December 2019 |
| Capital | 5,500,000 yen |
| Members | Chairman; Naohide Yamashita (Professor Emeritus, The University of Tokyo, Doctor of Medicine) |
| Location | Saito Bio Incubator, Room 312 7-7-15 Saito Asagi, Ibaraki-shi, Osaka 567-0085 Japan |
| Business | Research on diseases using genes and gene products, cells, and tissues, development of therapeutic methods, and sales of the results, etc. |
Access
Saito Bio Incubator, Room 312
7-7-15 Saito Asagi, Ibaraki-shi, Osaka 567-0085 Japan
A 10-minute walk from Saito-nishi Station on the Osaka Monorail Saito Line.
Profile
Chairman Naohide Yamashita
Professor Emeritus, University of Tokyo, Doctor of Medicine
| 1977 | Graduated from the University of Tokyo School of Medicine in 1977 |
|---|---|
| 2001–2016 | Professor, Institute of Medical Science, University of Tokyo |
| 2006–2010 | Director, Institute of Medical Science, University of Tokyo |
| 2019–present | Present Chairman of Novacellum inc. |
Message
Novacellum Inc. is engaged in the research and development of new therapies to meet the needs of society. Since immune checkpoint inhibitors became available in clinical practice, cancer immunotherapy has attracted significant attention. However, only a subset of patients benefit from these treatments, and further advances in cancer immunotherapy are eagerly awaited. In addition, personalized medicine using genomic information has progressed remarkably, and expectations are rising for neoantigen-based immunotherapies that combine these approaches with cancer immunotherapy.
Going forward, we will remain dedicated to developing new therapies that can bring hope to patients and will continue to devote our utmost efforts to this mission.
Chairman Naohide Yamashita